The impact of symptom burden on patient quality of life in chronic myeloid leukemia

Oncology (Switzerland)

Volumn 87, Issue 3, 2014, Pages 133-147

  Cella, David ^a   Nowinski, Cindy J ^a   Frankfurt, Olga ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adherence; Chronic myeloid leukemia; Health related quality of life; Symptom burden; Tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTARABINE; PONATINIB; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ANEMIA; BLEEDING; BONE MARROW DEPRESSION; BONE PAIN; CHRONIC MYELOID LEUKEMIA; FATIGUE; FEVER; FUNCTIONAL ASSESSMENT OF CANCER THERAPY LEUKEMIA; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LOSS OF APPETITE; MD ANDERSON SYMPTOM INVENTORY CHRONIC MYELOID LEUKEMIA; MEDICATION COMPLIANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NIGHT SWEAT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SATIETY; SPLENOMEGALY; TREATMENT RESPONSE; WEAKNESS; WEIGHT REDUCTION; ARTHRALGIA; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY SATISFACTION QUESTIONNAIRE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; EORTC QUALITY OF LIFE QUESTIONNAIRE; EROTC QLQ CML24; EUROPEAN QUALITY OF LIFE 5 DIMENSIONS; FLUID RETENTION; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANTIANGIOGENESIS THERAPY; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; HEADACHE; HOSPITALIZATION; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; MDASI CML; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; QUESTIONNAIRE; RASH; RATING SCALE; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; SKIN IRRITATION; SYMPTOM ASSESSMENT; THROMBOCYTOPENIA; TREATMENT REFUSAL; VOMITING; WEIGHT GAIN;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; TUMOR BURDEN;

EID: 84903861309     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000362816     Document Type: Review

References (77)

1. Bernards A, Rubin CM, Westbrook CA, Paskind M, Baltimore D: The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia. Mol Cell Biol 1987; 7: 3231-3236.
2. Nowell PC, Hungerford DA: Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960; 25: 85-109.
3. Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW: Success story of targeted therapy in chronic myeloid leukemia: a populationbased study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514-2520.
4. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J: Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981-1987.
5. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
6. Gleevec® (imatinib mesylate) (US). East Hanover, Novartis Pharmaceuticals Corporation, 2012 (prescribing information).
7. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197-2203.
8. Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Wang J, Ipina JJ, Kim DW, Ogura M, Pavlovsky C, Junghanss C, Milone JH, Nicolini FE, Robak T, Van Droogenbroeck J, Vellenga E, Bradley-Garelik MB, Zhu C, Hochhaus A: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123-1129.
9. Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicus L, Malhotra H, Powell C, Gogat K, Countouriotis AM, Gambacorti-Passerini C: Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486-3492.
10. American Cancer Institute: Cancer facts and figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf (accessed July 26, 2012).
11. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
12. Lee SJ: Chronic myelogenous leukaemia. Br J Haematol 2000; 111: 993-1009.
13. Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barate C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F: Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118: 4554-4560.
14. Hehlmann R: How I treat CML blast crisis. Blood 2012; 120: 737-747.
15. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ: International Randomized Study of Interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts) 2009; 114:abstract 1126.
16. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
17. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA: Six-year follow-up of patients receiving imatinib for the firstline treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061.
18. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
19. Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP: Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841-851.
20. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
21. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J: Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481-496.
22. Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD: A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin 2012; 28: 1155-1162.
23. Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, Apperley JF, Szydlo R, Desai R, Kozlowski K, Paliompeis C, Latham V, Foroni L, Molimard M, Reid A, Rezvani K, de Lavallade H, Guallar C, Goldman J, Khorashad JS: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388.
24. Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401-5411.
25. St. Charles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo DJ: Predictors of treatment nonadherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009; 114:abstract 2209.
26. Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61-69.
27. Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C: Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012; 28: 213-219.
28. Eliasson L, Clifford S, Barber N, Marin D: Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011; 35: 626-630.
29. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014; 32: 306-311.
30. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D: Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733-3736.
31. Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD: Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010; 26: 2861-2869.
32. Soni MK, Cella D: Quality of life and symptom measures in oncology: an overview. Am J Manag Care 2002; 8:S560-S573.
33. Food and Drug Administration: Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). 2009.
34. DeMuro C, Clark M, Mordin M, Fehnel S, Copley-Merriman C, Gnanasakthy A: Reasons for rejection of patientreported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010. Value Health 2012; 15: 443-448.
35. Cella D, Webster K, Du H, Lai JS, Jensen S, Rosen S, Tallman MS, Yount S: Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy -Leukemia (FACT-Leu) questionnaire. Value Health 2012; 15: 1051-1058.
36. Webster K, Chivington K, Shonk C, Eremenco S, Yount S, Hahn EA: Measuring quality of life (QOL) among patients with leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu). Qual Life Res 2002; 11: 678.
37. M.D. Anderson Cancer Center: The MD Anderson Symptom Inventory Chronic Myeloid Leukemia Module (MDASI-CML). http://www.mdanderson.org/education-and- research/departments-programs-and-labs/departments-and-divisions/ symptom-research/symptom-assessment-tools/mdasi-cml.html (accessed March 18, 2014).
38. Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE: Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013; 122: 641-647.
39. Efficace F, Breccia M, Saussele S, Kossak U, Caocci G, Sprangers M, Chie W, Naeem A, Nicolatou-Galitis O, Vignetti M, Cardoni A, Mandelli F, Baccarani M: International development of an EORTC measure to assess patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML). Blood (ASH Annual Meeting Abstracts) 2011; 118:abstract 3132.
40. Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F: International development of an EORTC questionnaire for assessing healthrelated quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 2013; 23: 825-836.
41. Laugsand EA, Sprangers MA, Bjordal K, Skorpen F, Kaasa S, Klepstad P: Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcomes 2010; 8: 104.
42. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D: Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the iris study. J Clin Oncol 2003; 21: 2138-2146.
43. Mauro MJ, Lipton JH, Miller CB, Ailawadhi S, Busque L, Akard LP, Pinilla-Ibarz J, Ericson S, Lin F, Cortes JE: Analysis of imatinib (IM)-related, low-grade (LG), non-hematologic (heme) adverse events (AEs) in patients (pts) with chronic myeloid leukemia (CML) switched to nilotinib (NIL): ENRICH study update. J Clin Oncol (ASCO Annual Meeting Abstracts) 2012; 30:abstract 6605.
44. Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M: Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 2011; 117: 5600-5606.
45. Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C: Safety and efficacy of bosutinib (SKI- 606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011; 118: 4567-4576.
46. Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Matloub Y, Chen T, Guilhot F: Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: A retrospective analysis of safety. J Clin Oncol (ASCO Annual Meeting Abstracts) 2008; 26:abstract 7015.
47. Nazha A, Williams LA, Kantarjian HM, Ault PS, Garcia-Gonzalez A, Williams JL, Probst A, O'Brien S, Jabbour E, Quintas-Cardama A, Shi Q, Cleeland CS, Cortes JE: Fatigue in chronic myelogenous leukemia patients (pts) treated with tyrosine kinase inhibitors (TKI). Blood (ASH Annual Meeting Abstracts) 2011; 118:abstract 3785.
48. Beaumont JL, Nowinski C, Coombs J, Szczudlo T, Blakesley RE, Gallagher NJ, Burns J, Cella D: Does baseline health-related quality of life or symptom burden predict clinical outcomes in patients with newly diagnosed CML-CP treated with nilotinib or imatinib? Blood (ASH Annual Meeting Abstracts) 2011; 118:abstract 1025.
49. Yount S, Kaiser K, Beaumont JL, Webster K, Wagner LI, Schenk TL, Kuzel T, Cella D: Development and validation of the functional assessment of cancer therapy: antiangiogenesis (FACT-AntiA). J Clin Oncol (ASCO Annual Meeting Abstracts) 2013; 31(suppl):abstract e20527.
50. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172.
51. Savage DG, Szydlo RM, Goldman JM: Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96: 111-116.
52. Kantarjian HM, Kim D-W, Issaragrisil S, Clark RE, Reiffers J, Nicolini FE, Pasquini R, Kalaycio M, Hughes TP, Hochhaus A, Kemp C, Fan X, Waltzman RJ, Saglio G, Larson RA: ENESTnd 4-year update: continued superiority of nilotinib vs imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP). Blood (ASH Annual Meeting Abstracts) 2012; 120:abstract 1676.
53. Hochhaus A, Shah NP, Cortes JE, Baccarani M, Bradley-Garelik MB, Dejardin D, Kantarjian H: Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. J Clin Oncol (ASCO Annual Meeting Abstracts) 2012; 30:abstract 6504.
54. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM: Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039-1043.
55. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony- Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
56. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM: Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013; 27: 107-112.
57. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540-3546.
58. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD: Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011; 117: 1141-1145.
59. Shah NP, Kantarjian HM, Kim DW, Rea D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A: Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26: 3204-3212.
60. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Muller MC, Lambert A, Matloub Y, Hochhaus A: Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010; 95: 232-240.
61. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators: A phase 2 trial of ponatinib in Philadelphia chromosome- positive leukemias. N Engl J Med 2013; 369: 1783-1796.
62. Iclusig® (ponatinib). Cambridge, ARIAD Pharmaceuticals, Inc., 2012, revised December 2013 (prescribing information).
63. EuroQoL Group: EuroQoL -a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
64. Rabin R, de Charro F: EQ-5D: A measure of health status from the EuroQoL group. Ann Med 2001; 33: 337-343.
65. Patel AA, Donegan D, Albert T: The 36-item short form. J Am Acad Orthop Surg 2007; 15: 126-134.
66. Stewart AL, Hays RD, Ware JE Jr: The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724-735.
67. Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA: Development of the cancer therapy satisfaction questionnaire: Item generation and content validity testing. Value Health 2005; 8:S41-S53.
68. Trask PC, Tellefsen C, Espindle D, Getter C, Hsu MA: Psychometric validation of the cancer therapy satisfaction questionnaire. Value Health 2008; 11: 669-679.
69. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
70. Knobel H, Loge JH, Brenne E, Fayers P, Hjermstad MJ, Kaasa S: The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 2003; 17: 664-672.
71. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J, et al: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
72. Bacik J, Mazumdar M, Murphy BA, Fairclough DL, Eremenco S, Mariani T, Motzer RJ, Cella D: The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 2004; 13: 137-154.
73. Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F, Sprangers M: Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol 2012; 91: 1371-1381.
74. Rea D, Maloisel F, Huguet F, Okada H, Bourdeix I, Nicolini FE, Tulliez M, Etienne G: EOSTA: an observational study on the compliance and quality of life (QoL) of chronic myeloid leukemia (CML) patients treated with second line nilotinib (Tasigna® ): interim results at 6 months of follow-up. Blood (ASH Annual Meeting Abstracts) 2011; 118:abstract 3782.
75. Trask PC, Cella D, Besson N, Kelly V, Masszi T, Kim DW: Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012; 36: 438-442.
76. Beaumont JL, Magestro M, Coombs J, Fan X, Kemp C, Waltzman RJ: Assessment of patient reported outcomes (PROs) from the ENESTnd trial with minimum follow-up of 36 cycles. Blood (ASH Annual Meeting Abstracts) 2012; 120:abstract 3166.
77. Cortes JE, Mauro MJ, Goldberg SL, Paquette R, Khoury HJ, Hirji I, Wagner S, Joo S, Davis C: Quality of life during early tyrosine kinase inhibitor treatment as self-reported by chronic myeloid leukemia patients participating in a prospective observational study (SIMPLICITY). Blood (ASH Annual Meeting Abstracts) 2011; 118:abstract 4435.